Loading...
Bhang Inc.
BHNG.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.02
CA$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $384670.00 in Q4 2021 to $363103.00 in Q3 2022. Gross profit remained healthy with margins at 75% in Q3 2022 compared to 53% in Q4 2021. Operating income hit -$773709.00 last quarter, sustaining a consistent -213% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.005M. Net income rose to -$981738.00, while earnings per share reached -$0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan